Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1995 Jan;146(1):111–120.

Effects of energy intake on type 1 plasminogen activator inhibitor levels in glomeruli of lupus-prone B/W mice.

D A Troyer 1, B Chandrasekar 1, T Thinnes 1, A Stone 1, D J Loskutoff 1, G Fernandes 1
PMCID: PMC1870784  PMID: 7856720

Abstract

Calorie restriction (CR) and/or reduced energy intake ameliorates the progression of autoimmune renal disease in (NZB x NZW)F1 (B/W) female mice and increases life span. Like other forms of glomerulonephritis, the lupus-like kidney disease observed in these animals is frequently accompanied by glomerular deposition of fibrin and increased accumulation of mesangial matrix. Because alterations in plasminogen activator inhibitor type 1 (PAI-1) expression or function may be involved in both fibrin deposition and accumulation of extracellular matrix, we have studied the effects of CR on the expression of PAI-1 in kidneys from female B/W mice fed either ad libitum or on a 40% CR diet. By immunohistochemistry and immunoblotting, we found that the glomerular levels of PAI-1 antigen were highest in older ad lib fed animals with more advanced glomerular disease. Increased levels of PAI-1 protein were paralleled by increased levels of PAI-1 mRNA in total RNA extracted from renal cortex and in diseased glomeruli as detected by in situ hybridization. CR diminished the accumulation of PAI-1 protein and reduced the expression of PAI-1 mRNA. Thus, glomeruli from animals fed ad lib showed much greater deposition of PAI-1 protein, increased expression of PAI-1 mRNA, and more severe histological abnormalities than animals on a CR diet. The differences between CR and ad lib animals were more pronounced in animals studied at 9 to 10 months versus those at 3 to 4 months of age. These observations indicate that the ameliorating effects of CR include diminished PAI-1 gene expression and decreased localization of PAI-1 in glomeruli.

Full text

PDF
111

Images in this article

115Figure 2
on p.115
116Figure 3
on p.116
117Figure 4
on p.117

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allred D. C., Clark G. M., Elledge R., Fuqua S. A., Brown R. W., Chamness G. C., Osborne C. K., McGuire W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 3;85(3):200–206. doi: 10.1093/jnci/85.3.200. [DOI] [PubMed] [Google Scholar]
  2. Andreasen P. A., Nielsen L. S., Kristensen P., Grøndahl-Hansen J., Skriver L., Danø K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem. 1986 Jun 15;261(17):7644–7651. [PubMed] [Google Scholar]
  3. Blasi F., Vassalli J. D., Danø K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987 Apr;104(4):801–804. doi: 10.1083/jcb.104.4.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chandrasekar B., Fernandes G. Decreased pro-inflammatory cytokines and increased antioxidant enzyme gene expression by omega-3 lipids in murine lupus nephritis. Biochem Biophys Res Commun. 1994 Apr 29;200(2):893–898. doi: 10.1006/bbrc.1994.1534. [DOI] [PubMed] [Google Scholar]
  5. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  6. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980 Jun 18;43(2):77–89. [PubMed] [Google Scholar]
  7. Falk R. J., Podack E., Dalmasso A. P., Jennette J. C. Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol. 1987 Apr;127(1):182–190. [PMC free article] [PubMed] [Google Scholar]
  8. Feng L., Tang W. W., Loskutoff D. J., Wilson C. B. Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis. J Am Soc Nephrol. 1993 May;3(11):1753–1764. doi: 10.1681/ASN.V3111753. [DOI] [PubMed] [Google Scholar]
  9. Fernandes G., Alonso D. R., Tanaka T., Thaler H. T., Yunis E. J., Good R. A. Influence of diet on vascular lesions in autoimmune-prone B/W mice. Proc Natl Acad Sci U S A. 1983 Feb;80(3):874–877. doi: 10.1073/pnas.80.3.874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fernandes G., Bysani C., Venkatraman J. T., Tomar V., Zhao W. Increased TGF-beta and decreased oncogene expression by omega-3 fatty acids in the spleen delays onset of autoimmune disease in B/W mice. J Immunol. 1994 Jun 15;152(12):5979–5987. [PubMed] [Google Scholar]
  11. Fernandes G., Friend P., Yunis E. J., Good R. A. Influence of dietary restriction on immunologic function and renal disease in (NZB x NZW) F1 mice. Proc Natl Acad Sci U S A. 1978 Mar;75(3):1500–1504. doi: 10.1073/pnas.75.3.1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fernandes G., Good R. A. Inhibition by restricted-calorie diet of lymphoproliferative disease and renal damage in MRL/lpr mice. Proc Natl Acad Sci U S A. 1984 Oct;81(19):6144–6148. doi: 10.1073/pnas.81.19.6144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fernandes G., Venkatraman J., Khare A., Horbach G. J., Friedrichs W. Modulation of gene expression in autoimmune disease and aging by food restriction and dietary lipids. Proc Soc Exp Biol Med. 1990 Jan;193(1):16–22. doi: 10.3181/00379727-193-42983. [DOI] [PubMed] [Google Scholar]
  14. Fernandes G., Yunis E. J., Good R. A. Influence of diet on survival of mice. Proc Natl Acad Sci U S A. 1976 Apr;73(4):1279–1283. doi: 10.1073/pnas.73.4.1279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Friend P. S., Fernandes G., Good R. A., Michael A. F., Yunis E. J. Dietary restrictions early and late: effects on the nephropathy of the NZB X NZW mouse. Lab Invest. 1978 Jun;38(6):629–632. [PubMed] [Google Scholar]
  16. Glass W. F., 2nd, Kreisberg J. I., Troyer D. A. Two-chain urokinase, receptor, and type 1 inhibitor in cultured human mesangial cells. Am J Physiol. 1993 Mar;264(3 Pt 2):F532–F539. doi: 10.1152/ajprenal.1993.264.3.F532. [DOI] [PubMed] [Google Scholar]
  17. Hekman C. M., Loskutoff D. J. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys. 1988 Apr;262(1):199–210. doi: 10.1016/0003-9861(88)90182-8. [DOI] [PubMed] [Google Scholar]
  18. Horbach G. J., Venkatraman J. T., Fernandes G. Food restriction prevents the loss of isosafrole inducible cytochrome P-450 mRNA and enzyme levels in aging rats. Biochem Int. 1990;20(4):725–730. [PubMed] [Google Scholar]
  19. Iwamoto T., Nakashima Y., Sueishi K. Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells. Kidney Int. 1990 Jun;37(6):1466–1476. doi: 10.1038/ki.1990.137. [DOI] [PubMed] [Google Scholar]
  20. Johnson R. J., Iida H., Alpers C. E., Majesky M. W., Schwartz S. M., Pritzi P., Gordon K., Gown A. M. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest. 1991 Mar;87(3):847–858. doi: 10.1172/JCI115089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Keeton M., Eguchi Y., Sawdey M., Ahn C., Loskutoff D. J. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol. 1993 Jan;142(1):59–70. [PMC free article] [PubMed] [Google Scholar]
  22. King A. J., Levey A. S. Dietary protein and renal function. J Am Soc Nephrol. 1993 May;3(11):1723–1737. doi: 10.1681/ASN.V3111723. [DOI] [PubMed] [Google Scholar]
  23. Korc M., Chandrasekar B., Yamanaka Y., Friess H., Buchier M., Beger H. G. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992 Oct;90(4):1352–1360. doi: 10.1172/JCI116001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lacave R., Rondeau E., Ochi S., Delarue F., Schleuning W. D., Sraer J. D. Characterization of a plasminogen activator and its inhibitor in human mesangial cells. Kidney Int. 1989 Mar;35(3):806–811. doi: 10.1038/ki.1989.56. [DOI] [PubMed] [Google Scholar]
  25. Laiho M., Saksela O., Keski-Oja J. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem. 1987 Dec 25;262(36):17467–17474. [PubMed] [Google Scholar]
  26. Loskutoff D. J. A slice of PAI. J Clin Invest. 1993 Dec;92(6):2563–2563. doi: 10.1172/JCI116866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Loskutoff D. J., Sawdey M., Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87–115. [PubMed] [Google Scholar]
  28. Masoro E. J., Yu B. P. Diet and nephropathy. Lab Invest. 1989 Feb;60(2):165–167. [PubMed] [Google Scholar]
  29. Mimuro J., Loskutoff D. J. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem. 1989 Mar 25;264(9):5058–5063. [PubMed] [Google Scholar]
  30. Mimuro J., Loskutoff D. J. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J Biol Chem. 1989 Jan 15;264(2):936–939. [PubMed] [Google Scholar]
  31. Morel-Maroger Striker L., Killen P. D., Chi E., Striker G. E. The composition of glomerulosclerosis. I. Studies in focal sclerosis, crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Lab Invest. 1984 Aug;51(2):181–192. [PubMed] [Google Scholar]
  32. Okuda S., Nakamura T., Yamamoto T., Ruoslahti E., Border W. A. Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9765–9769. doi: 10.1073/pnas.88.21.9765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Quax P. H., van den Hoogen C. M., Verheijen J. H., Padro T., Zeheb R., Gelehrter T. D., van Berkel T. J., Kuiper J., Emeis J. J. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem. 1990 Sep 15;265(26):15560–15563. [PubMed] [Google Scholar]
  34. Roberts A. B., Heine U. I., Flanders K. C., Sporn M. B. Transforming growth factor-beta. Major role in regulation of extracellular matrix. Ann N Y Acad Sci. 1990;580:225–232. doi: 10.1111/j.1749-6632.1990.tb17931.x. [DOI] [PubMed] [Google Scholar]
  35. Salant D. J., Belok S., Madaio M. P., Couser W. G. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest. 1980 Dec;66(6):1339–1350. doi: 10.1172/JCI109987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sappino A. P., Huarte J., Vassalli J. D., Belin D. Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest. 1991 Mar;87(3):962–970. doi: 10.1172/JCI115104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sawdey M. S., Loskutoff D. J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991 Oct;88(4):1346–1353. doi: 10.1172/JCI115440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Tomooka S., Border W. A., Marshall B. C., Noble N. A. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 1992 Dec;42(6):1462–1469. doi: 10.1038/ki.1992.442. [DOI] [PubMed] [Google Scholar]
  39. Tomosugi N., Wada T., Naito T., Takasawa K., Yokoyama H., Kida H., Kobayashi K. Role of plasminogen activator inhibitor on nephrotoxic nephritis and its modulation by tumor necrosis factor. Nephron. 1992;62(2):213–219. doi: 10.1159/000187035. [DOI] [PubMed] [Google Scholar]
  40. Villamediana L. M., Rondeau E., He C. J., Medcalf R. L., Peraldi M. N., Lacave R., Delarue F., Sraer J. D. Thrombin regulates components of the fibrinolytic system in human mesangial cells. Kidney Int. 1990 Nov;38(5):956–961. doi: 10.1038/ki.1990.297. [DOI] [PubMed] [Google Scholar]
  41. Werb Z., Mainardi C. L., Vater C. A., Harris E. D., Jr Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med. 1977 May 5;296(18):1017–1023. doi: 10.1056/NEJM197705052961801. [DOI] [PubMed] [Google Scholar]
  42. Wilcox J. N., Gee C. E., Roberts J. L. In situ cDNA:mRNA hybridization: development of a technique to measure mRNA levels in individual cells. Methods Enzymol. 1986;124:510–533. doi: 10.1016/0076-6879(86)24037-9. [DOI] [PubMed] [Google Scholar]
  43. Wilcox J. N., Smith K. M., Schwartz S. M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2839–2843. doi: 10.1073/pnas.86.8.2839. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES